Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[john302]

Lotus Pharm retains CCG Elite. Good stuff. On a side note I can't help but think it would be cool to see a merger between GTEC and Gold Horse and/or Lotus one day in the future.

Lotus Pharmaceuticals Inc. Retains CCG Elite
PR Newswire - January 14, 2008 8:30 AM ET


Related Quotes
Symbol Last Chg
LTUS Trade 1.00 0.00
Quotes delayed at least 15 minutes

Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or "the Company"), a leading pharmaceutical company in the People's Republic of China ("PRC"), today announced that it has retained CCG Elite to design and execute its investor relations campaign.

Through its GMP certified facilities, Lotus manufactures its own branded drugs and products for third-party distributors in China. The Company sells over 5,000 types of western, traditional Chinese medicines, and medical equipment via its extensive distribution network, covering over 300 distributors in 28 provinces, 1,000 hospitals, and 10 wholly owned and operated drug stores in Beijing. Additionally, Lotus offers contract research and development services. Novel branded drugs include Valsartan capsules for high blood pressure, which was Lotus' best selling drug in the first nine months of 2007; Brimonidine tartrate eyes drops for glaucoma; Levofloxacin lactate for infections; and Nicergoline injections for central nervous system complications, all of which are included in the national medical insurance catalog. For nine months ending September 30, 2007, net sales for Lotus totaled $37.6 million, up 50% from the same period in the prior year.

"We are a rapidly growing pharmaceutical manufacturer and distributor in China," said Dr. Liu Zhong Yi, Chairman, CEO and President of Lotus Pharmaceuticals, Inc. "We look forward to working with CCG Elite to increase our visibility in both the investment community and with the financial media as seek to maximize value to our shareholders.'

Pharmaceutical sales in the PRC are expected to rise by over 13 percent annually, reaching $24 billion by 2010. The demand for pharmaceutical products in the PRC is expected to increase rapidly over the coming years due to growing affluence, size of the middle class, and the aging population.

Lotus expects has a pipeline of over 20 branded generics and novel drugs, mainly in the cardiovascular and hormonal product markets. Furthermore, the Company plans to further expand its market share in Inner Mongolia, Anhui, and Beijing. Other growth strategies include direct sales of pharmaceuticals to hospitals, increasing its retail pharmacy presence in Beijing, and strategic acquisitions.

"Lotus is a leading pharmaceutical company with strong manufacturing capabilities, novel branded drugs, extensive distribution channels, and a strong management team," said Crocker Coulson, President of CCG Elite. "The Company is well-positioned to take advantage of increasing demand for pharmaceuticals in China. We intend to assist the Company to develop a broader following with fund managers and analysts focusing on high growth equities from China through an integrated investor relations program."

The Company maintains a representative office in the United States, where its Chief Financial Officer is located. For more information, refer to http://www.lotuseast.com .

About CCG Elite

CCG Elite is uniquely positioned to provide an outsourced, high-level investor relations solution that combines in-depth understanding of Asia's corporate culture and economic scene with a direct pipeline into the leading funds and broker-dealers in the United States. CCG Elite is a global, full- service investor relations agency with corporate headquarters in Los Angeles, and offices in New York, Newport Beach, Dallas, Hong Kong, Beijing and Shanghai. For further information, contact CCG Elite or visit the Company's website at http://www.ccgelite.com .

About Lotus Pharmaceuticals, Inc.

Established in 1999, Lotus Pharmaceuticals, Inc. ("Lotus") controls and operates Liang Fang Pharmaceutical, Ltd. ("Liang"') and En Zhe Jia Shi Pharmaceutical, Ltd. ("En Zhe"), two Chinese pharmaceutical companies located in Beijing. Liang and En Zhe form a large comprehensive enterprise, which deals in an integration of the production, trade, sales and marketing of pharmaceuticals. Together, they possess some of the most advanced pharmaceutical-production equipment used in China, workshops authenticated by the National GMP, a suite of various medicines produced by Liang and/or En Zhe (together, "Lotus East"), and a number of high-tech personnel. Lotus East has business and office facilities of 2,000 square meters, warehouse of 1,000 square meters and operates ten retail pharmacies in the Beijing area. Lotus East performs scientific research on new medicines, and the production, wholesale and retail sale of medicines. For more information, visit http://www.LotusEast.com .

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K filed with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

For more information, please contact:

Lotus Pharmaceuticals, Inc.
Mr. Adam Wasserman, CFO
Tel: [phone]
Email: [e-mail]

CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: [phone] (New York)
Email: [e-mail]

SOURCE Lotus Pharmaceuticals, Inc.

http://www.LotusEast.com